



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

DAVID L. PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

December 13, 2004

CERTIFICATE OF DELIVERY 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with FedEx addressed to: U.S. Patent and Trademark Office; 220 20th Street South; Customer Window, Mail Stop MS AMENDMENT; Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202, on the date below

December 13, 2004

Date

David L. Parker

U.S. Patent and Trademark Office
220 20th Street South
Customer Window, Mail Stop **MS AMENDMENT**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

RE: *U.S. Patent Application No. 10/784,537 entitled "AMINOPEPTIDASE A (APA) TARGETING PEPTIDES FOR THE TREATMENT OF CANCER" – Wadih Arap and Renata Pasqualini*
Our reference: UTSC:872US
Client reference: MDA00-025CIP1

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A39, B1-B18, and C1-C214.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:872US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker
Reg. No. 32,165

DLP/kmv
Encl.: as noted

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Wadih Arap
Renata Pasqualini

Serial No.: 10/784,537

Filed: February 23, 2004

For: AMINOPEPTIDASE A (APA)
TARGETING PEPTIDES FOR THE
TREATMENT OF CANCER



Group Art Unit: 1653

Examiner: Unknown

Atty. Dkt. No.: UTSC:872US

**CERTIFICATE OF DELIVERY
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with FedEx addressed to: U.S. Patent and Trademark Office; 220 20th Street South; Customer Window, Mail Stop MS AMENDMENT; Crystal Plaza Two, Lobby, Room 1B03; Arlington, VA 22202, on the date below:

December 13, 2004

Date

David L. Parker

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
220 20th Street South
Customer Window, Mail Stop MS AMENDMENT
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:872US.

This application is related by and subject matter to co-pending U.S. application numbers 10/363,202 filed March 7, 2003, 10/363,204 filed March 7, 2003, 10/363,203 filed March 7, 2003, 10/363,208 filed March 7, 2003, 10/484,550 filed January 20, 2004, 10/489,071 filed March 8, 2004, 10/940,004 filed September 13, 2004, 09/765,101 filed January 17, 2001, and 10/363,205 filed September 2, 2003.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: December 13, 2004

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Wadih Arap Renata Pasqualini	
(Use several sheets if necessary)	Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3

U.S. Patent Documents

Exam. Init.	Ref. Des	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2001/0046498	11/29/01	Rouslahti <i>et al.</i>	424	178.1	1/17/01
	A2	2003/0113320	6/19/03	Ruoslahti <i>et al.</i>	424	143.1	10/03/02
	A3	4,472,509	9/18/84	Gansow and Strand	436	548	6/07/82
	A4	4,912,040	3/27/90	Kaufman and Dorner	435	69.6	2/03/87
	A5	5,021,236	6/04/91	Gries <i>et al.</i>	424	9	3/02/87
	A6	5,081,034	1/14/92	Bevilasqua <i>et al.</i>	435	252.33	11/14/88
	A7	5,098,833	03/24/92	Lasky <i>et al.</i>	435	69.1	2/23/89
	A8	5,188,964	2/23/93	McGuire <i>et al.</i>	436	64	4/12/90
	A9	5,206,347	4/27/93	Ruoslahti <i>et al.</i>	530	413	7/13/90
	A10	5,216,131	6/01/93	Lasky <i>et al.</i>	435	69.1	2/23/89
	A11	5,223,409	6/29/93	Ladner <i>et al.</i>	435	69.7	3/01/91
	A12	5,225,538	7/06/93	Capon <i>et al.</i>	530	387.3	12/16/91
	A13	5,270,163	12/14/93	Gold <i>et al.</i>	435	6	8/17/92
	A14	5,288,846	2/22/94	Quertermous <i>et al.</i>	435	172.3	8/03/92
	A15	5,304,640	4/19/94	Asky <i>et al.</i>	536	23.5	2/13/92
	A16	5,415,874	5/16/95	Bender <i>et al.</i>	424	520	10/31/89
	A17	5,428,130	6/27/95	Capon <i>et al.</i>	530	350	12/08/92
	A18	5,453,362	9/26/95	Lamarco <i>et al.</i>	435	69.1	4/12/93
	A19	5,463,026	10/31/95	Nakamura and Sato	530	387.3	2/24/94
	A20	5,492,807	2/20/96	Santi	435	5	11/19/93
	A21	5,506,126	4/09/96	Seed <i>et al.</i>	435	172.3	1/18/93

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Wadih Arap Renata Pasqualini	
	Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>

U.S. Patent Documents

Exam. Init.	Ref. Des	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A22	5,536,814	7/16/96	Ruoslahti <i>et al.</i>	530	329	3/11/94
	A23	5,622,699	4/22/97	Ruoslahti <i>et al.</i>	424	93.6	9/11/95
	A24	5,670,312	9/23/97	Santi	435	5	11/17/95
	A25	5,688,692	11/18/97	Jat <i>et al.</i>	435	354	2/11/93
	A26	5,688,935	11/18/97	Stephens <i>et al.</i>	536	23.1	5/03/95
	A27	5,705,610	1/06/98	Zuckerman <i>et al.</i>	530	338	10/01/93
	A28	5,750,344	5/12/98	Doyle	435	6	10/04/95
	A29	5,840,841	11/24/98	Zuckerman <i>et al.</i>	530	338	5/08/97
	A30	5,866,759	2/02/99	Jat <i>et al.</i>	800	3	7/02/97
	A31	5,902,598	5/11/99	Chen and Ashton	424	423	8/28/97
	A32	5,955,572	9/21/99	Ruoslahti and Pasqualini	530	317	5/14/98
	A33	6,068,829	5/30/00	Ruoslahti and Pasqualini	242	9.1	6/23/97
	A34	6,174,861	1/16/01	O'Reilly and Folkman	514	12	7/07/99
	A35	6,232,440	5/15/01	Hillman <i>et al.</i>	530	350	4/20/99
	A36	6,350,855	2/26/02	Tobin	530	350	9/15/97
	A37	6,399,384	6/04/02	Jat	435	456	9/15/00
	A38	6,458,381	10/01/02	Sourovov and Jung	424	450	2/12/97
	A39	6,528,281	3/04/03	Tobin	435	69.1	6/14/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	DE 19605175	8/14/97	Germany			Abstract

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B2	EP 0639584	4/01/98	Europe			English
	B3	WO 02/20723	3/14/02	WIPO			English
	B4	WO 02/20822	3/14/02	WIPO			English
	B5	WO 03/022991	3/20/03	WIPO			English
	B6	WO 92/00091	7/01/91	WIPO			English
	B7	WO 92/03461	3/05/92	WIPO			English
	B8	WO 92/06191	4/16/92	WIPO			English
	B9	WO 95/14714	6/01/95	WIPO			English
	B10	WO 96/34874	11/07/96	WIPO			English
	B11	WO 96/34875	11/07/96	WIPO			English
	B12	WO 97/10507	3/20/97	WIPO			English
	B13	WO 97/19954	5/06/97	WIPO			English
	B14	WO 97/30024	9/16/99	WIPO			English
	B15	WO 97/39021	10/23/97	WIPO			English
	B16	WO 98/10795	3/19/98	WIPO			English
	B17	WO 99/46284	9/16/99	WIPO			English
	B18	WO 99/57311	11/11/99	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Aiello <i>et al.</i> , "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins," <i>Proc. Natl. Acad. Sci., USA</i> , 92(23):10457-10461, 1995.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C2	Aiello <i>et al.</i> , "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders," <i>N. Eng. J. Med.</i> , 331(22):1480-1487, 1994.
	C3	Alliot <i>et al.</i> , "Brain parenchyma vessels and the angiotensin system," <i>Brain Res.</i> , 830:101-112, 1999.
	C4	Alliot <i>et al.</i> , "Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin," <i>J. Neurosci. Res.</i> , 58:367-378, 1999.
	C5	Alon <i>et al.</i> , "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity," <i>Nat. Med.</i> , 1:1024-1028, 1995.
	C6	Andrade <i>et al.</i> , "Angiotensin-II-induced angiogenesis in sponge implants in mice," <i>Int. J. Microcirc. Clin. Exp.</i> , 16(6):302-307, 1996.
	C7	Arap <i>et al.</i> , "Steps toward mapping the human vasculature by phage display," <i>Nature Med.</i> , 8(2):121-127, 2002.
	C8	Arap <i>et al.</i> , "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," <i>Science</i> , 279:377-380, 1998.
	C9	Arap <i>et al.</i> , "Chemotherapy targeted to tumor vasculature," <i>Curr. Opin. Oncol.</i> , 10(6):560-565, 1998.
	C10	Arap <i>et al.</i> , "Targeting the prostate for destruction through a vascular address," <i>Proc. Natl. Acad. Sci., USA</i> , 99:1527-1531, 2002.
	C11	Arden, "The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment," <i>Br. J. Ophthalmol.</i> , 85:366-370, 2001.
	C12	Asako <i>et al.</i> , "Organic solvent tolerance and antibiotic resistance increased by overexpression of marA in <i>Escherichia coli</i> ," <i>Applied Environmental Microbiology</i> , 63(4):1428-1433, 1997.
	C13	Assmann <i>et al.</i> , "A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection," <i>J. Exp. Med.</i> , 175:623-635, 1992.
	C14	Atkins <i>et al.</i> , "Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation," <i>Bone</i> , 26(6):653-661, 2000.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Wadih Arap Renata Pasqualini	
	Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C15	Baillie <i>et al.</i> , "Tumor vasculature-A potential therapeutic target," <i>British J. Cancer</i> , 72:257-267, 1995.
	C16	Baringa, "Peptide-guided cancer drugs show promise in mice," <i>Science</i> , 279:323-324, 1998.
	C17	Baumann <i>et al.</i> , "Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells," <i>J. Immunol.</i> , 157(1):284-290, 1996.
	C18	Beckman <i>et al.</i> , "Experimental manipulation of the rodent visceral yolk sac," <i>Teratology</i> , 41(4):395-404, 1990.
	C19	Behm <i>et al.</i> , "Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;13) and MLL gene rearrangements," <i>Blood</i> , 87:1134-1139, 1996.
	C20	Bergelson <i>et al.</i> , "Isolation of a common receptor for Cocksackie B viruses and adenoviruses 2 and 5," <i>Science</i> , 275:1320-1322, 1997.
	C21	Bergers <i>et al.</i> , "Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors," <i>J. Clin. Invest.</i> , 111(9):1287-1295, 2003.
	C22	Bicknell, "Vascular targeting and the inhibition of angiogenesis," <i>Annals of Oncology</i> , 5(Suppl 4):S45-S50, 1994.
	C23	Bigner <i>et al.</i> , "Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin sulfate proteoglycan Mel-14F(ab1)2-a preliminary report," <i>J. Neuro-Oncol.</i> , 24:109-122, 1995.
	C24	Bogenreider <i>et al.</i> , "Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue," <i>Prostate</i> , 33:225-232, 1997.
	C25	Brooks <i>et al.</i> , "Anti integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> , 96:1815-1822, 1995.
	C26	Brooks <i>et al.</i> , "Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels," <i>Cell</i> , 79(7):1157-1164, 1994.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C27	Brooks <i>et al.</i> , "Requirement of vascular integrin $\alpha v \beta 3$ for angiogenesis," <i>Science</i> , 264:569-571, 1994.
	C28	Bumol <i>et al.</i> , "Monoclonal antibody and antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth," <i>Proc. Natl. Acad. Sci., USA</i> , 80:529-533, 1983.
	C29	Burg <i>et al.</i> , "A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen," <i>Exp. Cell Res.</i> , 235:254-264, 1997.
	C30	Burg <i>et al.</i> , "Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules," <i>J. Biol. Chem.</i> , 271(42):26110-26116, 1996.
	C31	Burg <i>et al.</i> , "Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells," <i>J. Cell. Physiol.</i> , 177:299-312, 1998.
	C32	Burg <i>et al.</i> , "NG2 proteoglycan-binding peptides target tumor neovasculature," <i>Cancer Res.</i> , 59(12):2869-2874, 1999.
	C33	Burioni <i>et al.</i> , "Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro," <i>Proc. Natl. Acad. Sci., USA</i> , 91:355-359, 1994.
	C34	Burrows and Thorpe, "Vascular targeting-A new approach to the therapy of solid tumors," <i>Pharmac. Ther.</i> , 64:155-174, 1994.
	C35	Burton <i>et al.</i> , "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," <i>Proc. Natl. Acad. Sci., USA</i> , 88:10134-10137, 1991.
	C36	Butner, "Retinitis pigmentosa and retinal neovascularization: a case report," <i>Ann. Ophthalmol.</i> , 16:861-865, 1984.
	C37	Cai <i>et al.</i> , "Induction of glucose regulated proteins during growth of a murine tumor," <i>J. Cell Physiol.</i> , 154(2):229-237, 1993.
	C38	Campbell <i>et al.</i> , "Prohibitin 3' untranslated region polymorphism and breast cancer risk," <i>Cancer Epidemiol. Biomarkers Prev.</i> , 12(11 pt1):1273-1274, 2003.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C39	Campfield and Smith, "Overview: neurobiology of OB protein (leptin)," Proceedings of the Nutrition Society, 57:429-440, 1998.
	C40	Campfield <i>et al.</i> , "Strategies and potential molecular targets for obesity treatment," <i>Science</i> , 280:1383-1387, 1998.
	C41	Cao <i>et al.</i> , "Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases," <i>J. Clin. Invest.</i> , 101:1055-1063, 1998.
	C42	Cattani <i>et al.</i> , "Cloning and characterization of human recombinant antibody Fab fragments specific for types 1 and 2 herpes simplex virus," <i>Microbiologica</i> , 18:135-142, 1995.
	C43	Chaveroche <i>et al.</i> , "A rapid method for efficient gene replacement in the filamentous fungus <i>Aspergillus nidulans</i> ," <i>Nucleic Acids Research</i> , 28(22):E97, 2000.
	C44	Chen <i>et al.</i> , "Thapsigargin-induced grp78 expression is mediated by the increase of cytosolic free calcium in 9L rat brain tumor cells," <i>J. Cell. Biochem.</i> , 78:404-416, 2000.
	C45	Chinni <i>et al.</i> , "Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients," <i>Clin. Cancer Res.</i> , 3:1557-1564, 1997.
	C46	Choongkittaworn <i>et al.</i> , "Expression of prohibitin in rat seminiferous epithelium," <i>Biol. Reprod.</i> , 49(2):300-310, 1993.
	C47	Curnis <i>et al.</i> , "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)," <i>Nat Biotechnol.</i> , (11):1185-90, 2000.
	C48	D'Amato <i>et al.</i> , "Thalidomide is an inhibitor of angiogenesis," <i>Proc. Natl. Acad. Sci., USA</i> , 91:4082-4085, 1994.
	C49	Davis <i>et al.</i> , "Use of a high affinity DNA ligand in flow cytometry," <i>Nucleic Acids Research</i> , 24:702-706, 1996.
	C50	Delpino <i>et al.</i> , "Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin," <i>Mol. Membr. Biol.</i> , 15(1):21-26, 1998.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C51	Deo <i>et al.</i> , "Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood," <i>J. Immunology</i> , 160:1677-1686, 1998.
	C52	Dmitriev <i>et al.</i> , "An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism," <i>J. Virol.</i> , 72(12):9706-9713, 1998.
	C53	Douglas <i>et al.</i> , "Targeted gene delivery by tropism-modified adenoviral vectors," <i>Nature Biotech.</i> , 14:1574-1578, 1996.
	C54	Drolet <i>et al.</i> , "An enzyme-linked oligonucleotide assay," <i>Nat. Biotech.</i> , 14:1021-1025, 1996.
	C55	Duh <i>et al.</i> , "Vascular endothelial growth factor and diabetes," <i>Diabetes</i> , 48:1899-1906, 1997.
	C56	Dvorak <i>et al.</i> , "Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies," <i>Cancer Cells</i> , 3:77-85, 1991.
	C57	Egeblad and Werb, "New functions for the matrix metalloproteinases in cancer progression," <i>Nat. Rev. Cancer</i> , 2:161-174, 2002.
	C58	Ellerby <i>et al.</i> , "Anti-cancer activity of targeted pro-apoptotic peptides," <i>Nature Med.</i> , 5(9):1032-8, 1999.
	C59	Finnell, "Teratology: general considerations and principles," <i>J. Allergy Clin. Immunol.</i> , 103(2 Pt 2):S337-42, 1999.
	C60	Folkman, "Addressing tumor blood vessels," <i>Nature Biotechnology</i> , 15:510, 1997.
	C61	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Biotechnol.</i> , 1:27-31, 1995.
	C62	Fujimura <i>et al.</i> , "Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression," <i>Oncology</i> , 58:342-352, 2000.
	C63	Furuya <i>et al.</i> , "The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin," <i>Cancer Res.</i> , 54(23):6167-6175, 1994.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C64	Fusaro <i>et al.</i> , "Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling," <i>J. Biol. Chem.</i> , 278(48):47853-47861, 2003.
	C65	Geng <i>et al.</i> , "Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon alpha in renal cell carcinomas," <i>Anticancer Res.</i> , 18:1-7, 1998.
	C66	Giordano <i>et al.</i> , "Biopanning and rapid analysis of selective interactive ligands," <i>Nat. Med.</i> , 7(11):1249-1253, 2001.
	C67	Girod <i>et al.</i> , "Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2," <i>Nature Med.</i> , 5:1052-1056, 1999.
	C68	Goetz <i>et al.</i> , "Lu-ECAM-1-mediated adhesion of melanoma cells to endothelium under conditions of flow," <i>Int. J. Cancer</i> , 65:192-199, 1996.
	C69	Gold <i>et al.</i> , "Diversity of oligonucleotide functions," <i>Annu. Rev. Biochem.</i> , 64:763-797, 1995.
	C70	Goldman <i>et al.</i> , "Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor," <i>Cancer Res.</i> , 57(8):1447-51, 1997.
	C71	Goodson <i>et al.</i> , "High-affinity urokinase receptor antagonists identified with bacteriophage peptide display," <i>Proc. Natl. Acad. Sci., USA</i> , 91:7129-7133, 1994.
	C72	Grako and Stallcup, "Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor," <i>Exp. Cell Res.</i> , 221:231-240, 1995.
	C73	Grasso <i>et al.</i> , "In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140," <i>Endocrinology</i> , 138(4):1413-1418, 1997.
	C74	Grifman <i>et al.</i> , "Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids," <i>Mol. Ther.</i> , 3(6):964-75, 2001.
	C75	Griscelli <i>et al.</i> , "Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest," <i>Proc. Natl. Acad. Sci., USA</i> , 95:6367-6372, 1998.
	C76	Hadigan <i>et al.</i> , "Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial," <i>J. Amer. Med. Assn.</i> , 284:472-477, 2000.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Wadih Arap Renata Pasqualini	
	Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C77	Hammes <i>et al.</i> , "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Med.</i> , 2:529-533, 1996.
	C78	Hanahan, "Signaling vascular morphogenesis and maintenance," <i>Science</i> , 277:48-50, 1997.
	C79	Harper and Reisfeld, "Cell-associated proteoglycans in human malignant melanoma," <i>Biology of Proteoglycans</i> , Acad. Press, 345-366, 1987.
	C80	Harper and Reisfeld, "Inhibition of anchorage independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan," <i>J. Natl. Cancer Inst.</i> , 71:259-263, 1983.
	C81	Hart <i>et al.</i> , "Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide," <i>J. Biol. Chem.</i> , 269:12468-12474, 1994.
	C82	Hashizume <i>et al.</i> , "Openings between defective endothelial cells explain tumor vessel leakiness," <i>Am. J. Pathol.</i> , 156(4):1363-1380, 2000.
	C83	Hayakawa <i>et al.</i> , "Clinical features of autosomal dominant retinitis pigmentosa with rhodopsin gene codon 17 mutation and retinal neovascularization in a Japanese patient," <i>Am. J. Ophthalmol.</i> , 115:168-173, 1993.
	C84	Hicke <i>et al.</i> , "DNA aptamers block L-selectin function in vivo," <i>J. Clin. Invest.</i> , 98:2688-2692, 1996.
	C85	Hong <i>et al.</i> , "Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells," <i>EMBO J.</i> , 16:2294-2306, 1997.
	C86	Huang <i>et al.</i> , "Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature," <i>Science</i> , 275:547-550, 1997.
	C87	Iida <i>et al.</i> , "Spreading and focal contact formation of human melanoma cells in response to the stimulation of both NG2 $\alpha 4 \beta 1$ integrin," <i>Cancer Res.</i> , 55:2177-2185, 1995.
	C88	Ikonen <i>et al.</i> , "Prohibitin, an antiproliferative protein, is localized to mitochondria," <i>FEBS Letters</i> , 358(3):273-277, 1995.
	C89	Ino <i>et al.</i> , "Expression of aminopeptidase A in human gestational choriocarcinoma cell lines and tissues," <i>Placenta</i> , 21:63-72, 2000.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C90	Jackson, In: <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , Hardman (eds.), McGraw-Hill Medical Publishing Division, 809-841, 2001.
	C91	Jain <i>et al.</i> , "Metabolic complications associated with antiretroviral therapy," <i>Antiviral Res.</i> , 51:151-177, 2001.
	C92	Joliot <i>et al.</i> , "alpha-2,8-Polysialic acid is the neuronal surface receptor of antenna pedia homeobox peptide," <i>New Biol.</i> , 3:1121-1131, 1991.
	C93	Joliot <i>et al.</i> , "Antenna pedia homeobox peptide regulates neural morphogenesis," <i>Proc. Natl. Acad. Sci., USA</i> , 88:1864-1868, 1991.
	C94	Juillerat-Jeanneret <i>et al.</i> , "Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta," <i>Lab. Invest.</i> , 80(6):973-980, 2000.
	C95	Juillerat-Jeanneret <i>et al.</i> , "Regulation of peptidase activity in a three-dimensional aggregate model of brain tumor vasculature," <i>Cell Tissue Res.</i> , 311:53-59, 2003.
	C96	Jupe <i>et al.</i> , "The 3' untranslated region of prohibitin and cellular immortalization," <i>Exp. Cell Res.</i> , 224(1):128-135, 1996.
	C97	Kahler <i>et al.</i> , "Chronic administration of OB protein decreases food intake by selectively reducing meal size in male rats," <i>Am J Physiol</i> , 275(1 Pt 2):R180-R185, 1998.
	C98	Kerbel, "Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents," <i>BioEssays</i> , 13(1):31-36, 1991.
	C99	Kiang <i>et al.</i> , "17 beta-estradiol-induced increases in glucose-related protein 78kD and 94kD protect human breast cancer T47-D cells from thermal injury," <i>Chin. J. Physiol.</i> , 40(4):213-219, 1997.
	C100	Kifor and Dzau, "Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins," <i>Circ. Res.</i> , 60:422-428, 1987.
	C101	Kiovunen <i>et al.</i> , "Identification of receptor ligands with phage display peptide libraries," <i>J. Nuclear Medicine</i> , 40(5):883-888, 1999.
	C102	Koivunen <i>et al.</i> , "Integrin-binding peptides derived from phage display libraries," <i>Methods Mol. Biol.</i> , 129:3-17, 1999.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C103	Koivunen <i>et al.</i> , "Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins," <i>Biotechnology</i> , 13(3):265-270, 1995.
	C104	Koivunen <i>et al.</i> , "Selection of peptides binding to the alpha5 beta1 integrin from phage display library," <i>J. Biol. Chem.</i> , 268:20205-20210, 1993.
	C105	Koivunen <i>et al.</i> , "Tumor targeting with a selective gelatinase inhibitor," <i>Nat. Biotechnol.</i> , 17:768-774, 1999.
	C106	Kolonin <i>et al.</i> , "Molecular addresses in blood vessels as targets for therapy," <i>Curr. Opin. Chem. Biol.</i> , 5:308-313, 2001.
	C107	Kolonin <i>et al.</i> , "Teratogenicity induced by targeting a placental immunoglobulin transporter," <i>Proc. Natl. Acad. Sci., USA</i> , 99(20):13055-13060, 2002.
	C108	Lahdenranta <i>et al.</i> , "An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration," <i>Proc. Natl. Acad. Sci., USA</i> , 98(18):10368-10373, 2001.
	C109	Lamers and Bacher, "Prohibitin and prohibitone, ubiquitous and abundant proteins that are reluctant to reveal their real identity," <i>Int. Arch. Allergy Immunol.</i> , 113(1-3):146-149, 1997.
	C110	Lappi, "Tumor targeting through fibroblast growth factor receptors," <i>Cancer Biology</i> , 6:279-288, 1995.
	C111	Larocca <i>et al.</i> , "Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage," <i>FEBS J.</i> , 13:727-734, 1999.
	C112	Le Noble <i>et al.</i> , "The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network," <i>J. Vasc. Res.</i> , 33(6):480-488, 1996.
	C113	Le Roux <i>et al.</i> , "Neurotrophic activity of the Antenna pedia homeodomain depends on its specific DNA-binding properties," <i>Proc. Natl. Acad. Sci., USA</i> , 90:9120-9124, 1993.
	C114	Leff, "NeXstar previews 'PASS' for downstream synthesis of therapeutic oligos," <i>Bioworld Today</i> , 8:2&4, 1997.
	C115	Leger <i>et al.</i> , "The chondroitin sulfate proteoglycan NG2 is a tumor specific antigen on the chemically induced rat chondrosarcoma HSN," <i>Int. J. Cancer</i> , 58:700-705, 1994.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C116	Li <i>et al.</i> , "Widespread tissue distribution of aminopeptidase A, an evolutionarily conserved ectoenzyme recognized by the BP-1 antibody," <i>Tissue Antigens</i> , 42:488-496, 1993.
	C117	Lin <i>et al.</i> , "T and B cell development in BP-1/6C3/aminopeptidase A-deficient mice," <i>J. Immunol.</i> , 160(10):4681-4687, 1998.
	C118	Look <i>et al.</i> , "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N," <i>J. Clin. Invest.</i> , 83:1299-1307, 1999.
	C119	Makinen <i>et al.</i> , "Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1," 274(30):21217-22, 1999.
	C120	Mandecki <i>et al.</i> , "A mathematical model for biopanning (affinity selection) using peptide libraries on filamentous phage," <i>J. Theor. Biol.</i> , 176:523-530, 1995.
	C121	Manjeshwar <i>et al.</i> , "Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer," <i>Cancer Res.</i> , 63(17):5251-5256, 2003.
	C122	Maranghi <i>et al.</i> , "Evaluation of the placenta: suggestions for a greater role in developmental toxicology," <i>Adv. Exp. Med. Biol.</i> , 444:129-136, 1998.
	C123	Martin <i>et al.</i> , "Retrovirus targeting by tropism restriction to melanoma cells," <i>J. Virol.</i> , 73:6923-6929, 1999.
	C124	Martiny-Baron and Marmé, VEGF-mediated tumor angiogenesis: a new target for cancer therapy," <i>Curr. Opin. Biotech.</i> , 6:675-680, 1995.
	C125	McCarty <i>et al.</i> , "Quantitative and qualitative in vivo angiogenesis assay," <i>Int. J. Oncol.</i> , 21(1):5-10, 2002.
	C126	McClung <i>et al.</i> , "Prohibitin: potential role in senescence, development, and tumor suppression," <i>Exp. Gerontol.</i> , 30(2):99-124, 1995.
	C127	McConnell <i>et al.</i> , "Biopanning phage display libraries using magnetic beads vs. polystyrene plates," <i>BioTechniques</i> , 26(2):208-209, 1999.
	C128	Mentzel <i>et al.</i> , "Induction of albuminuria in mice: synergistic effect of two monoclonal antibodies directed to different domains of aminopeptidase A," <i>Kidney Int.</i> , 55(4):1335-1347, 1999.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C129	Miller <i>et al.</i> , "Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer," <i>Cancer Res.</i> , 58:5738, 5748, 1998.
	C130	Miner <i>et al.</i> , "Clonal drift of cell surface, melanogenic and experimental metastatic properties of in vivo-selected, brain meninges-colonizing murine B16 melanoma," <i>Cancer Research</i> , 42:4631-4638, 1982.
	C131	Misra <i>et al.</i> , "The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction," <i>J Biol Chem.</i> , 277(44):42082-7, 2002.
	C132	Monton <i>et al.</i> , "Effects of angiotensin II on endothelial cell growth: role of AT-1 and AT-2 receptors," <i>J. Am. Soc. Nephrol.</i> , 9(6):969-974, 1998.
	C133	Morikawa <i>et al.</i> , "Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors," <i>Am. J. Pathol.</i> , 160(3):985-1000, 2002.
	C134	Murphy <i>et al.</i> , "Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation," <i>J. Cell Physiol.</i> , 157(2):351-358, 1993.
	C135	Mustonen and Alitalo, "Endothelial receptor tyrosine kinases involved in angiogenesis," <i>J. Cell Biol.</i> , 129:895-898, 1995.
	C136	Nadal <i>et al.</i> , "Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF- β and BDGF-BB," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:739-748, 2002.
	C137	Nagy <i>et al.</i> , "Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent," <i>Proc. Natl. Acad. Sci., USA</i> , 93:7269-7273, 1996.
	C138	Nagy <i>et al.</i> , "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin," <i>Proc. Natl. Acad. Sci., USA</i> , 95:1794-1799, 1998.
	C139	Nanus <i>et al.</i> , "Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A," <i>Proc. Natl. Acad. Sci., USA</i> , 90:7069-7073, 1993.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C140	Nelson, "Parenting of therapeutics for obesity and nutritional disease," Exp Opin Ther Patents, 9(9):1185-1196, 1999.
	C141	Nishiyama and Stallcup, "Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface," <i>Mol. Biol. Cell</i> , 4:1097-1108, 1993.
	C142	Nishiyama <i>et al.</i> , "Interaction between NG2 proteoglycan and PDGF α receptor is required for optimal response to PDGF," <i>J. Neurosci. Res.</i> , 43:315-330, 1996.
	C143	Nishiyama <i>et al.</i> , "The primary structure of NG2, a novel membrane-spanning proteoglycan," <i>J. Cell. Biol.</i> , 114:359-371, 1991.
	C144	Nuell <i>et al.</i> , "Prohibitin, an evolutionary conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells," <i>Mol. Cell Biol.</i> , 11(3):1372-1381, 1991.
	C145	Okamoto <i>et al.</i> , "Transgenic mice with increased expression of vascular endothelial growth factor in the retina," <i>Am. J. Pathol.</i> , 151(1):281-291, 1997.
	C146	Oloffson <i>et al.</i> , "Phage viability in organic media: insights into phage stability," <i>J Mol Recognit</i> , 11(1-6):91-93, abstract, 1998.
	C147	Olofsson <i>et al.</i> , "Current biology of VEGF-B and VEGF-C," <i>Curr. Op. Biotechnol.</i> , 10:528-535, 1999.
	C148	Owens <i>et al.</i> , "Cloning the antibody response in humans with chronic inflammatory disease: immunopanning of subacute sclerosing panencephalitis (SSPE) brain sections with antibody phage libraries prepared from SSPE brain enriches for antibody recognizing measles virus antigens in situ," <i>J. Virol.</i> , 74(3):1533-1537, 2000.
	C149	Pasqualini and Ruoslahti, "Organ targeting in vivo using phage display peptide libraries," <i>Nature</i> , 380:364-366, 1996.
	C150	Pasqualini <i>et al.</i> , "A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins," <i>J. Cell Biol.</i> , 130:1189-1196, 1995.
	C151	Pasqualini <i>et al.</i> , "Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis," <i>Cancer Res.</i> , 60(3):722-727, 2000.
	C152	Pasqualini <i>et al.</i> , " α integrins as receptors for tumor targeting by circulating ligands," <i>Nature Biotechnology</i> , 15:542-546, 1997.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Wadih Arap Renata Pasqualini	
	Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C153	Pasqualini <i>et al.</i> , In: <i>Phage Display: A Laboratory Manual</i> , eds. Barbas <i>et al.</i> , Cold Spring Harbor Laboratory Press, New York, NY, 22.1-24, 2000.
	C154	Pasqualini, "Vascular targeting with phage peptide libraries," <i>J. Nucl. Med.</i> , 43(2):159-162, 1999.
	C155	Pauli <i>et al.</i> , "Organ-preference of metastasis," <i>Cancer and Metastasis Reviews</i> , 9:175-189, 1990.
	C156	Pereboeva <i>et al.</i> , "Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with a chimeric antigen," <i>J. Med. Virol.</i> , 60:144-151, 2000.
	C157	Pereboeva <i>et al.</i> , "Identification of antigenic sites on three hepatitis C virus proteins using phage-displayed peptide libraries," <i>J. Med. Virol.</i> , 56:105-111, 1998.
	C158	Pierce <i>et al.</i> , "Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity," <i>Arch. Ophthalmol.</i> , 114:1219-1228, 1996.
	C159	Pierce <i>et al.</i> , "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <i>Proc. Natl. Acad. Sci., USA</i> , 92(3):905-909, 1995.
	C160	Pluschke <i>et al.</i> , "Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan," <i>Proc. Natl. Acad. Sci., USA</i> , 93:9710-9715, 1996.
	C161	Prezzi <i>et al.</i> , "Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients," <i>J. Immunol.</i> , 156:4504-4513, 1996.
	C162	Pruett, "Retinitis pigmentosa: clinical observations and correlations," <i>Trans. Am. Ophthalmol. Soc.</i> , 81:693-735, 1983.
	C163	Rajotte and Ruoslahti, "Membrane dipeptidase is the receptor for a lung -targeting peptide identified by in vivo phage display," <i>J. Biol. Chem.</i> , 274:11593-11598, 1999.
	C164	Rajotte <i>et al.</i> , "Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display," <i>J. Biol. Chem.</i> , 274(17):11593-11598, 1999.
	C165	Rajotte <i>et al.</i> , "Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display," <i>J. Clin. Invest.</i> , 102(2):430-437, 1998.

25480466.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C166	Rak <i>et al.</i> , "Consequences of angiogenesis for tumor progression, metastasis and cancer therapy," <i>Anti-Cancer Drugs</i> , 6:3-18, 1995.
	C167	Raulin <i>et al.</i> , "Human immunodeficiency virus and host cell lipid. Interesting pathways in research for a new HIV therapy," <i>Prog. Lipid Res.</i> , 41:27-65, 2002.
	C168	Real <i>et al.</i> , "Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity, analysis, and comparison of antigen expression in cultured cells and tissues," <i>Cancer Res.</i> , 45:4401-4411, 1985.
	C169	Riordan, "Patents," <i>The New York Times</i> , Monday, September 15, 1997.
	C170	Roof and Makino, "Structure and function of retinal photoreceptors," <i>Principles and Practice of Ophthalmology</i> , W.B. Saunders Company, Philadelphia, 2000.
	C171	Roux <i>et al.</i> , "Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone," <i>J. Cell Physiol.</i> , 168(3):489-498, 1996.
	C172	Rugh, <i>The Mouse: Its Reproduction and Development</i> , Oxford Science Publications, Oxford, 1990.
	C173	Sang, "Complex role of matrix metalloproteinase in angiogenesis," <i>Cell Res.</i> , 8(3):171-177, 1998.
	C174	Schlingemann <i>et al.</i> , "Aminopeptidase a is a constituent of activated pericytes in angiogenesis," <i>J. Pathol.</i> , 179(4):436-442, 1996.
	C175	Schlingemann <i>et al.</i> , "Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissues," <i>Amer. J. Path.</i> , 138:1335-1347, 1991.
	C176	Schlingemann <i>et al.</i> , "Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds," <i>Amer. J. Path.</i> , 136:1393-1405, 1990.
	C177	Schrappe <i>et al.</i> , "Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells," <i>Cancer Res.</i> , 51:4986-4993, 1991.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Wadih Arap Renata Pasqualini	
	Filing Date: February 23, 2004	Group: 1653
	U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C178	Scott and Smith, "Searching for peptide ligands with an epitope library," <i>Science</i> , 249:386-390, 1990.
	C179	Smith and Scott, "Libraries of peptides and proteins displayed in filamentous phage," <i>Meth. Enzymol.</i> , 21:228-257, 1993.
	C180	Smith <i>et al.</i> , "Oxygen-induced retinopathy in the mouse," <i>Invest. Ophthalmol.</i> , 35(1):101-111, 1994.
	C181	Smith, "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface," <i>Science</i> , 228:1315-1317, 1985.
	C182	Spitler <i>et al.</i> , "Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin immunotoxin," <i>Cancer Res.</i> , 47:1717-1723, 1987.
	C183	Spurdle <i>et al.</i> , "The prohibitin 3' untranslated region polymorphism is not associated with risk of ovarian cancer," <i>Gynecol. Oncol.</i> , 90(1):145-149, 2003.
	C184	St. Croix <i>et al.</i> , "Genes expressed in human tumor endothelium," <i>Science</i> , 289(5482):1197-1202, 2000.
	C185	Stone <i>et al.</i> , "Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia," <i>J. Neurosci.</i> , 15(7):4738-4747, 1995.
	C186	Tanaka <i>et al.</i> , "Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA," <i>Cancer Res.</i> , 58(15):3362-9, 1998.
	C187	Tillet <i>et al.</i> , "The membrane-spanning proteoglycan NG2 binds to collagen V and VI through central non-helical portion of the ectodomain," <i>J. Biol. Chem.</i> , 272:10769-10776, 1997.
	C188	Trepel <i>et al.</i> , "Molecular adaptors for vascular-targeted adenoviral gene delivery," <i>Hum Gene Ther.</i> , 11(14):1971-81, 2000.
	C189	Triantafilou <i>et al.</i> , "Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface," <i>Hum. Immunol.</i> , 62(8):764-770, 2001.
	C190	Tsimanis <i>et al.</i> , "Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia," <i>Leuk. Lymphoma</i> , 42(1-2):195-205, 2001.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C191	Uliss <i>et al.</i> , "Retinitis pigmentosa and retinal neovascularization," <i>Ophthalmology</i> , 93:1599-1603, 1986.
	C192	Verma and Somia, "Gene therapy-promises, problems, and prospects," <i>Nature</i> , 389:239-242, 1997.
	C193	Volpert <i>et al.</i> , "Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats," <i>J. Clin. Invest.</i> , 98(3):671-679, 1996.
	C194	Walsh <i>et al.</i> , "Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma," <i>Br. J. Pharmacol.</i> , 120(7):1302-1311, 1997.
	C195	Wang <i>et al.</i> , "Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function," <i>Oncogene</i> , 18(23):3501-3510, 1999.
	C196	Watkins <i>et al.</i> , "The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery," <i>Gene Ther.</i> , 4:1004-1012, 1997.
	C197	Watson <i>et al.</i> , "Variability among human umbilical vein endothelial cultures," <i>Science</i> , 268:447-448, 1995.
	C198	Weitzman <i>et al.</i> , "Adenovirus vectors in cancer gene therapy," In: <i>Gene Therapy Technology and Vector Systems</i> , 2:17-25, 1997.
	C199	Whaley <i>et al.</i> , "Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly," <i>Nature</i> , 405:665-668, 2000.
	C200	Wickham <i>et al.</i> , "Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies," <i>J. Virol.</i> , 70:6831-6838, 1996.
	C201	Wickham <i>et al.</i> , "Targeted adenovirus-mediated gene delivery to T cells via CD3," <i>J. Virol.</i> , 71(10):7663-7669, 1997.
	C202	Wickham <i>et al.</i> , "Targeting adenovirus," <i>Gene Ther.</i> , 7:110-114, 2000.
	C203	Wickham <i>et al.</i> , "Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation," <i>Cancer Immunol. Immunother.</i> , 45:149-151, 1997.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:872US	Serial No. 10/784,537
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap Renata Pasqualini	
		Filing Date: February 23, 2004	Group: 1653
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C204	Wu <i>et al.</i> , "Molecular cloning of the murine BP-1/6C3 antigen: a member of the zinc-dependent metallopeptidase family," <i>Proc. Natl. Acad. Sci., USA</i> , 87(3):993-997, 1990.
	C205	Wu, "In vivo veritas: live phage display panning," <i>Nature Biotechnology</i> , 14:429-431, 1996.
	C206	Yang and Reisfeld, "Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice," <i>Proc. Natl. Acad. Sci., USA</i> , 85:1189-1193, 1988.
	C207	Yanovski <i>et al.</i> , "Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy," <i>J. Clin. Endocrin. Metab.</i> , 84(6):1925-1931, 1999.
	C208	Yoshiji <i>et al.</i> , "The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor," <i>Clin. Cancer Res.</i> , 7(4):1073-1078, 2001.
	C209	Zempo <i>et al.</i> , "Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 16:28-33, 1996.
	C210	Zhang <i>et al.</i> , "Crystal structure of the obese protein leptin-E100," <i>Nature</i> , 387:206-209, 1997.
	C211	Zhang <i>et al.</i> , "Development and application of adenoviral vectors for gene therapy of cancer," <i>Cancer Gene Therapy</i> , 6:113-138, 1999.
	C212	Zhang <i>et al.</i> , "Inhibition of adipocyte differentiation by HIV protease inhibitors," <i>J. Clin. Endocrin. Metab.</i> , 84:4274-4277, 1999.
	C213	Zhang <i>et al.</i> , "Positional cloning of the mouse obese gene and its human homologue," <i>Nature</i> , 372:425-432, 1994.
	C214	Zhu <i>et al.</i> , "Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule," <i>Proc. Natl. Acad. Sci., USA</i> , 88:9568-9572, 1991.

25480466.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.